2,227 Shares in United Therapeutics Corporation $UTHR Acquired by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,227 shares of the biotechnology company’s stock, valued at approximately $1,207,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management raised its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth about $31,000. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on UTHR shares. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Trading Up 1.9%

Shares of UTHR stock opened at $518.27 on Wednesday. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The company’s 50-day moving average price is $534.53 and its 200-day moving average price is $536.74. The stock has a market cap of $22.23 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the business earned $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $506.59, for a total value of $4,812,605.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $164,359,579.37. This represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 452,575 shares of company stock valued at $245,684,184 in the last 90 days. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.